These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29870627)

  • 41. [First NOAk specific antidote as additional safety factor in therapy].
    MMW Fortschr Med; 2016 Feb; 158(2):66-7. PubMed ID: 27017635
    [No Abstract]   [Full Text] [Related]  

  • 42. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program.
    Fanikos J; Murwin D; Gruenenfelder F; Tartakovsky I; França LR; Reilly PA; Kermer P; Wowern FV; Lane DA; Butcher K
    Thromb Haemost; 2020 Jan; 120(1):27-35. PubMed ID: 31470445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).
    O'Malley PA
    Clin Nurse Spec; 2015; 29(5):262-4; quiz E8. PubMed ID: 26258832
    [No Abstract]   [Full Text] [Related]  

  • 45. Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort.
    Barber PA; Wu TY; Ranta A
    Neurology; 2020 May; 94(19):e1968-e1972. PubMed ID: 32079737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.
    Vornicu O; Larock AS; Dincq AS; Douxfils J; Dogné JM; Mullier F; Lessire S
    Expert Opin Biol Ther; 2017 Oct; 17(10):1275-1296. PubMed ID: 28728489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incomplete dabigatran reversal with idarucizumab.
    Steele AP; Lee JA; Dager WE
    Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacologic Reversal of Direct Oral Anticoagulants.
    Farina N; Miller JT
    Crit Care Nurs Q; 2018; 41(2):121-128. PubMed ID: 29494368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The first experience with dabigatran antidote in the University Hospital Pilsen].
    Šlechtová J; Hajšmanová Z; Lavičková A; Šigutová P
    Cas Lek Cesk; 2016; 155(8):442-444. PubMed ID: 28098476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Antidote Is Finally Here! Idarucizumab, A Specific Reversal Agent for the Anticoagulant Effects of Dabigatran.
    O'Malley PA
    Clin Nurse Spec; 2016; 30(2):81-3; quiz E9. PubMed ID: 26848896
    [No Abstract]   [Full Text] [Related]  

  • 51. Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
    Hofer S; Philipsenburg C; Weigand MA; Brenner T
    A A Case Rep; 2016 Dec; 7(11):227-231. PubMed ID: 27669031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Successful treatment of severe dabigatran intoxication with idarucizumab in a patient with acute kidney injury].
    Poulsen CG; Bestle M; Boesby L
    Ugeskr Laeger; 2017 Feb; 179(7):. PubMed ID: 28397672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The use of Idarucizumab in intracerebral bleeding - a case report].
    Hummel BA; Senger S; Schleicher C; Eichler H
    Dtsch Med Wochenschr; 2018 Jul; 113(13):961-964. PubMed ID: 29972840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New - direct oral anticoagulants: actual review].
    Michalcová J; Penka M; Buliková A; Zavřelová J; Štěpařová A
    Vnitr Lek; 2016; 62(10):805-813. PubMed ID: 27900867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Idarucizumab for dabigatran overdose.
    Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
    Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
    Darius H
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage.
    Kuramatsu JB; Sembill JA; Huttner HB
    Crit Care; 2019 Jun; 23(1):206. PubMed ID: 31171018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Idarucizumab: What Should We Know?
    Cortese F; Calculli G; Gesualdo M; Cecere A; Zito A; De Vito F; Carbonara R; Carbonara S; Cortese AM; Ciccone MM
    Curr Drug Targets; 2018; 19(1):81-88. PubMed ID: 28950812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.